Method for using gene expression to determine prognosis of prostate cancer

A method for determining a likelihood of cancer recurrence in a patient with prostate cancer, comprising:

• measuring an expression level of at least one microRNA in a biological sample comprising prostate tissue obtained from the patient, wherein the at least one microRNA is a microRNA selected from hsa-miR-93;
• hsa-miR-106b;
• hsa-miR-21;
• hsa-miR-449a;
• hsa-miR-182;
• hsa-miR-27a;
• hsa-miR-103;
• hsa-miR-141;
• hsa-miR-92a;
• hsa-miR-22;
• hsa-miR-29b;
• hsa-miR-210;
• hsa-miR-331;
• hsa-miR-191;
• hsa-miR-425;
• hsa-miR-200c;
• hsa-miR-30e-5p;
• hsa-miR-133a;
• hsa-miR-30a;
• hsa-miR-222;
• hsa-miR-1;
• hsa-miR-145;
• hsa-miR-486-5p;
• hsa-miR-19b;
• hsa-miR-205;
• hsa-miR-31;
• hsa-miR-155;
• hsa-miR-206;
• hsa-miR-99a;
• and hsa-miR-146b-5p;
• and
• normalizing said expression level to obtain a normalized expression level;
• wherein a normalized expression level of hsa-miR-93;
• hsa-miR-106b;
• hsa-miR-21;
• hsa-miR-449a;
• hsa-miR-182;
• hsa-miR-27a;
• hsa-miR-103;
• hsa-miR-141;
• hsa-miR-92a;
• hsa-miR-22;
• hsa-miR-29b;
• hsa-miR-210;
• hsa-miR-331;
• hsa-miR-191;
• hsa-miR-425;
• and hsa-miR-200c is positively associated with an increased risk of recurrence;
• and
• wherein a normalized expression level of hsa-miR-30e-5p;
• hsa-miR-133a;
• hsa-miR-30a;
• hsa-miR-222;
• hsa-miR-1;
• hsa-miR-145;
• hsa-miR-486-5p;
• hsa-miR-19b;
• hsa-miR-205;
• hsa-miR-31;
• hsa-miR-155;
• hsa-miR-206;
• hsa-miR-99a;
• and hsa-miR-146b-5p is negatively associated with an increased risk of recurrence.